...Stefano Molica; Marco Rossi; David Allsup In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus...

... treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response. The decrease in the production of the amyloidogenic light chains is a required condition to obtain the organ response, which is commonly delayed. Meanwhile, supportive...

... transplantation (HSCT) or immunosuppressive therapy (IST) comprising antithymocyte globulin (ATG) with cyclosporine (CsA) as initial treatment for AA patients. With limited epidemiological data on the clinical management of AA in Asia, a prospective cohort registry study involving 22 AA treatment centers in China...

..., a pursuit for organ involvement is essential, with a focus on heart involvement, even in the absence of suggestive symptoms for involvement, as this has both prognostic and treatment implications. Details regarding initial treatment options, including stem cell transplantation, are provided in this review...

...Ron D. Jachimowicz; Andreas Engert Cancer in the adolescent and young adult (AYA) is the second leading cause of nonaccidental death with hematological malignancies spiking during this period. Treatment of AYAs with hematological malignancies usually follows either pediatric or adult protocols...

... to in the content or advertisements. Complete remission Non-Hodgkin’s lymphomas Treatment Hemato-Oncology and Hemato-Immunology. Proc. 2nd Int. Conf., Catania 1986 Acta haemat. 78: suppl. l,pp. 157-162(1987...

...A. Tefferi The recent discovery of an eosinophilia-specific, imatinib-sensitive, karyotypically occult but fluorescence in situ hybridization-apparent molecular lesion in a subset of patients with blood eosinophilia has transformed the diagnostic as well as treatment approach to eosinophilic...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. T cell prolymphocytic leukemia Chromosome rearrangements Karyotype Treatment...

...J. Jaime Caro; Alexandra Ward; Traci Craig Green; Krista Huybrechts; Alejandro Arana; Suzanne Wait; Androulla Eleftheriou Objective: To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs...

... and tumor bulk used to identify high-risk patients with non-Hodgkin’s lymphomas, do not appear to correlate with disease activity or prognosis in AILD. Treatment of AILD has been unsatisfactory, with approximately 25% of patients achieving complete and sustained remission when combined chemotherapy agents...